Investigators within the Big Ten Cancer Research Consortium recently presented results from the Phase Ib portion of the BTCRC-GU14-003 study, establishing the maximum tolerated dose of pembrolizumab and bevacizumab in combination for subjects with metastatic clear cell renal carcinoma after failure of at least one systemic therapy for metastatic disease.
In a poster session presented at the 2016 Genitourinary Cancers Symposium in San Francisco in January, investigators reported no dose-limiting toxicities or serious adverse events related to the study drug had been reported. The 200 mg fixed dose of pembrolizumab and 15 mg/kg dose of bevacizumab, both given every three weeks, was determined to be safe and recommended for a multicenter Phase 2 study that is ongoing. (See abstract.) Read More
Feb. 1, 2016: A conversation with Anas Al-Janadi, MD, associate professor of medicine at the Michigan State University College of Human Medicine, chief of the Division of Hematology/Oncology and medical director of the MSU Breslin Cancer Center, a member of the Big Ten Cancer Research Consortium. Q: How do you think cancer research will change in the next 10 to 20 years? We believe strongly that collaboration is the best possible way to conduct cancer research without expanding the cost, particularly at a time when government funding for medical research has remained stagnant. But collaboration offers many other... Read More
Feb. 1, 2016: In this month's Q&A, Big Ten Cancer Research Consortium (Big Ten CRC) Administrative Headquarters addresses common questions related to correlative research. In what aspects of a clinical trial are correlative research managers at Big Ten CRC Administrative Headquarters able to assist? As clinical trials continue to increase in complexity and further emphasize translational science, the collection of correlative specimens and the succeeding specimen analysis becomes ever more important. To ensure this process is carried out effectively, the correlative managers act as the point of contact for sites to answer any correlative questions that may arise. Read More
Jan. 27, 2016: All 69 National Cancer Institute (NCI)-designated cancer centers, including nine members of the Big Ten Cancer Research Consortium, have issued a joint statement urging HPV vaccination for the prevention of cancer. About 79 million people in the United States are currently infected with a human papillomavirus (HPV) according to the Centers for Disease Control and Prevention (CDC), and 14 million new infections occur each year. Several types of high-risk HPV are responsible for the vast majority of cervical, anal, oropharyngeal (middle throat) and other genital cancers. While many of these cancers are preventable through the HPV vaccine, vaccination rates across the U.S. remain low. Read more in the following news releases: Read More
Jan. 20, 2016: The Big Ten Cancer Research Consortium's "Across the Consortium" is your front-row seat to all the latest action in cancer research conducted by our member institutions. Read More
Jan. 12, 2016 According to the National Cancer Institute, an estimated 12,900 new cases of cervical cancer occurred in the United States in 2015. The disease also caused an estimated 4,100 deaths. But the dawn of 2016 ushers in exciting opportunities for a new year of progress in cancer research, prevention, and treatment. January is National Cervical Cancer Awareness Month, and member institutions of the Big Ten Cancer Research Consortium are leading the fight against this highly preventable, highly treatable cancer. Discovering disparity: Study addresses disparity in cervical cancer deaths While studying cervical cancer statistics compiled by the... Read More
Jan. 4, 2016: A conversation with Arkadiusz Dudek, MD, PhD, professor of medicine, hematology/oncology, at the University of Illinois College of Medicine. Dr. Dudek is a member of both the University of Illinois Cancer Center and the BTCRC Steering Committee. Q: How do you think cancer research will change in the next 10 to 20 years? Portable technology is changing research every day. From apps to scanners, information transmission is faster than ever before. In development at the University of Illinois is a portable blood drop test for lung cancer screening. The way a drop of blood can alter the course of daily treatment for a... Read More
Dec. 18, 2015: As the year is winding down Big Ten university researchers have not lost their momentum. As we look back over this past year, great accomplishments along with generous grants and gifts are the hallmarks worthy of celebration. Big Ten CRC members are committed to improving treatment paradigms, and they continue to do just that through rigorously investigating correlations with far-reaching effects. A few examples include new insight into restoring cancer suppressor activity to damaged genes and identifying specific genes correlated with lung cancer tumor formation and metastasis; a comprehensive study that shows the relationship of mastectomy to survival; and new developments that promise to revolutionize clinical tests used in diagnosing and treating different cancers. We look forward... Read More
Dec. 11, 2015: Thank you to all who contributed to the Big Ten Cancer Research Consortium’s success over the past year. Together we have achieved new milestones, increased participation within clinical trial working groups, and expanded both the number and diversity of concepts in the consortium’s pipeline. During this holiday season, we are grateful for what we have accomplished. Following are just a few highlights: Read More
Dec. 11, 2015:What are the responsibilities of Big Ten CRC regulatory managers? Big Ten CRC regulatory managers assist with all aspects of regulatory issues related to Big Ten CRC research, including interactions with consortium members, institutional review boards, and regulatory agencies. Regulatory services include: Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube